Morse Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History

Morse Asset Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-13,040	Closed	-$1.02M	–	141
2019 Q1	$1.02M	Sell	13,040 -1,788	-12%	-$135K	0.31%	71
2018 Q4	$1.25M	Sell	14,828 -1,170	-7%	-$125K	0.45%	56
2018 Q3	$2.74M	Buy	15,998 +160	+1%	+$24.1K	0.72%	44
2018 Q2	$2.05M	Buy	15,838 +5,643	+55%	+$630K	0.56%	52
2018 Q1	$1.05M	Buy	10,195 +4,576	+81%	+$453K	0.29%	81
2017 Q4	$480K	Sell	5,619 -22,361	-80%	-$1.94M	0.13%	100
2017 Q3	$2.38M	Buy	27,980 +13,745	+97%	+$1.09M	0.71%	50
2017 Q2	$1.08M	Buy	+14,235	New	+$996K	0.35%	73

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Morse Asset Management's LGND Position: Q2 2019 in Review

Morse Asset Management sold out of Ligand Pharmaceuticals (LGND) in Q2 2019, closing a stake of 13,040 shares — an estimated $1.02M sold.

Morse Asset Management first reported a position in LGND in Q2 2017 and held it in 8 quarters. The position peaked at $2.74M in Q3 2018. 305 funds tracked by Wall St. Rank hold LGND as of Q2 2019.

Morse Asset Management reported no remaining Ligand Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Morse Asset Management sold 13,040 Ligand Pharmaceuticals shares in Q2 2019, an estimated $1.02M.
Morse Asset Management first reported a position in Ligand Pharmaceuticals in Q2 2017 and held it in 8 quarters.
Morse Asset Management's Ligand Pharmaceuticals position peaked at $2.74M in Q3 2018.
305 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2019.

Based on Morse Asset Management's 13F filing for Q2 2019, filed 1 Aug 2019.